{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:04:10Z","timestamp":1792177450178,"version":"4.4.0"},"reference-count":92,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2014,2,4]],"date-time":"2014-02-04T00:00:00Z","timestamp":1391472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,2,4]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>This paper provides a thorough overview of the current advances in diagnosis and therapy of myasthenia gravis (MG). Nowadays the term \u2018myasthenia gravis\u2019 includes heterogeneous autoimmune diseases, with a postsynaptic defect of neuromuscular transmission as the common feature. Myasthenia gravis should be classified according to the antibody specificity [acetylcholine, muscle-specific receptor tyrosine kinase (MuSK), low-density lipoprotein receptor-related protein 4 (LRP4), seronegative], thymus histology (thymitis, thymoma, atrophy), age at onset (in children; aged less than or more than 50 years) and type of course (ocular or generalized). With optimal treatment, the prognosis is good in terms of daily functions, quality of life and survival. Symptomatic treatment with acetylcholine esterase inhibition is usually combined with immunosuppression. Azathioprine still remains the first choice for long-term immunosuppressive therapy. Alternative immunosuppressive options to azathioprine include cyclosporin, cyclophosphamide, methotrexate, mycophenolate mofetil and tacrolimus. Rituximab is a promising new drug for severe generalized MG. Emerging therapy options include belimumab, eculizumab and the granulocyte\u2013 macrophage colony-stimulating factor. One pilot study on etanercept has given disappointing results. For decades, thymectomy has been performed in younger adults to improve non-paraneoplastic MG. However, controlled prospective studies on the suspected benefit of this surgical procedure are still lacking. In acute exacerbations, including myasthenic crisis, intravenous immunoglobulin, plasmapheresis and immunoadsorption are similarly effective.<\/jats:p>","DOI":"10.1111\/cei.12217","type":"journal-article","created":{"date-parts":[[2013,10,12]],"date-time":"2013-10-12T02:37:13Z","timestamp":1381545433000},"page":"408-418","source":"Crossref","is-referenced-by-count":231,"title":["Myasthenia gravis: an update for the clinician"],"prefix":"10.1093","volume":"175","author":[{"given":"J P","family":"Sieb","sequence":"first","affiliation":[{"name":"Department of Neurology, HELIOS Hanseklinikum Stralsund, University Hospital Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,2,4]]},"reference":[{"key":"2021122010012694500_cei12217-bib-0001","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1212\/WNL.0b013e318217e735","article-title":"Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada","volume":"76","author":"Pakzad","year":"2011","journal-title":"Neurology"},{"key":"2021122010012694500_cei12217-bib-0002","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1159\/000328863","article-title":"Change in myasthenia gravis epidemiology in Trento, Italy, after twenty years","volume":"36","author":"Pallaver","year":"2011","journal-title":"Neuroepidemiology"},{"key":"2021122010012694500_cei12217-bib-0003","doi-asserted-by":"crossref","first-page":"572","DOI":"10.2169\/internalmedicine.44.572","article-title":"Increase in incidence of elderly-onset patients with myasthenia gravis in Nagano Prefecture, Japan","volume":"44","author":"Matsuda","year":"2005","journal-title":"Intern Med"},{"key":"2021122010012694500_cei12217-bib-0004","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1007\/s00415-012-6478-6","article-title":"Characteristics of late-onset myasthenia gravis","volume":"259","author":"Zivkovic","year":"2012","journal-title":"J Neurol"},{"key":"2021122010012694500_cei12217-bib-0005","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in \u2018seronegative\u2019 myasthenia gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"key":"2021122010012694500_cei12217-bib-0006","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1242\/dev.038711","article-title":"To build a synapse: signaling pathways in neuromuscular junction assembly","volume":"137","author":"Wu","year":"2010","journal-title":"Development"},{"key":"2021122010012694500_cei12217-bib-0007","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"key":"2021122010012694500_cei12217-bib-0008","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00415-011-6194-7","article-title":"Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis","volume":"259","author":"Pevzner","year":"2012","journal-title":"J Neurol"},{"key":"2021122010012694500_cei12217-bib-0009","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archneurol.2011.2393","article-title":"Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis","volume":"69","author":"Zhang","year":"2012","journal-title":"Arch Neurol"},{"key":"2021122010012694500_cei12217-bib-0010","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/brain\/awl095","article-title":"MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis","volume":"129","author":"Farrugia","year":"2006","journal-title":"Brain"},{"key":"2021122010012694500_cei12217-bib-0011","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1212\/WNL.0b013e31827b907b","article-title":"Complete stable remission and autoantibody specificity in myasthenia gravis","volume":"80","author":"Baggi","year":"2013","journal-title":"Neurology"},{"key":"2021122010012694500_cei12217-bib-0012","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.nmd.2008.03.006","article-title":"Severe neonatal myasthenia due to maternal anti-MuSK antibodies","volume":"18","author":"Behin","year":"2008","journal-title":"Neuromuscul Disord"},{"key":"2021122010012694500_cei12217-bib-0013","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jneuroim.2012.05.011","article-title":"Anti-MuSK- and anti-AChR-positive myasthenia gravis induced by d-penicillamine","volume":"250","author":"Poulas","year":"2012","journal-title":"J Neuroimmunol"},{"key":"2021122010012694500_cei12217-bib-0014","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3109\/08916930903555943","article-title":"Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction","volume":"43","author":"Gomez","year":"2010","journal-title":"Autoimmunity"},{"key":"2021122010012694500_cei12217-bib-0015","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ana.21371","article-title":"Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction","volume":"63","author":"Cole","year":"2008","journal-title":"Ann Neurol"},{"key":"2021122010012694500_cei12217-bib-0016","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1212\/WNL.0b013e318237f660","article-title":"Anti-MuSK autoantibodies block binding of collagen Q to MuSK","volume":"77","author":"Kawakami","year":"2011","journal-title":"Neurology"},{"key":"2021122010012694500_cei12217-bib-0017","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"key":"2021122010012694500_cei12217-bib-0018","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/mus.21533","article-title":"Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience","volume":"41","author":"Pasnoor","year":"2010","journal-title":"Muscle Nerve"},{"key":"2021122010012694500_cei12217-bib-0019","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jneuroim.2008.01.013","article-title":"Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1","volume":"195","author":"Niks","year":"2008","journal-title":"J Neuroimmunol"},{"key":"2021122010012694500_cei12217-bib-0020","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1212\/01.WNL.0000150587.71497.B6","article-title":"Thymus changes in anti-MuSK-positive and -negative myasthenia gravis","volume":"64","author":"Lauriola","year":"2005","journal-title":"Neurology"},{"key":"2021122010012694500_cei12217-bib-0021","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.20386","article-title":"Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG","volume":"57","author":"Leite","year":"2005","journal-title":"Ann Neurol"},{"key":"2021122010012694500_cei12217-bib-0022","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"Diaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"2021122010012694500_cei12217-bib-0023","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jns.2006.05.065","article-title":"High-dose intravenous immunoglobulin for the treatment of MuSK antibody-positive seronegative myasthenia gravis","volume":"247","author":"Takahashi","year":"2006","journal-title":"J Neurol Sci"},{"key":"2021122010012694500_cei12217-bib-0024","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1212\/WNL.49.5.1454","article-title":"Paraneoplastic myasthenia gravis: detection of anti-MGT30 (titin) antibodies predicts thymic epithelial tumor","volume":"49","author":"Voltz","year":"1997","journal-title":"Neurology"},{"key":"2021122010012694500_cei12217-bib-0025","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/CCO.0b013e32834ea6bb","article-title":"Multidisciplinary treatment of malignant thymoma","volume":"24","author":"Spaggiari","year":"2012","journal-title":"Curr Opin Oncol"},{"key":"2021122010012694500_cei12217-bib-0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11748-011-0814-0","article-title":"Thymoma and thymic carcinoma","volume":"60","author":"Venuta","year":"2012","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"2021122010012694500_cei12217-bib-0027","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1212\/WNL.0b013e31825644ff","article-title":"Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients","volume":"78","author":"Leite","year":"2012","journal-title":"Neurology"},{"key":"2021122010012694500_cei12217-bib-0028","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1177\/1352458511431728","article-title":"Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature","volume":"18","author":"Jarius","year":"2012","journal-title":"Mult Scler"},{"key":"2021122010012694500_cei12217-bib-0029","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/archneur.63.6.851","article-title":"Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy","volume":"63","author":"Kister","year":"2006","journal-title":"Arch Neurol"},{"key":"2021122010012694500_cei12217-bib-0030","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1001\/archneurol.2009.231","article-title":"Herzmyasthenie: myasthenia of the heart","volume":"66","author":"Aarli","year":"2009","journal-title":"Arch Neurol"},{"key":"2021122010012694500_cei12217-bib-0031","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1001\/archneurol.2009.229","article-title":"Autoimmune targets of heart and skeletal muscles in myasthenia gravis","volume":"66","author":"Suzuki","year":"2009","journal-title":"Arch Neurol"},{"key":"2021122010012694500_cei12217-bib-0032","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1007\/s00415-011-6344-y","article-title":"Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis","volume":"259","author":"Romi","year":"2012","journal-title":"J Neurol"},{"key":"2021122010012694500_cei12217-bib-0033","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/mus.23296","article-title":"Myasthenia gravis: sleep quality, quality of life, and disease severity","volume":"46","author":"De Lapiscina","year":"2012","journal-title":"Muscle Nerve"},{"key":"2021122010012694500_cei12217-bib-0034","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1212\/01.wnl.0000254620.45529.97","article-title":"Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis","volume":"68","author":"Deymeer","year":"2007","journal-title":"Neurology"},{"key":"2021122010012694500_cei12217-bib-0035","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1196\/annals.1405.004","article-title":"Thymectomy for nonthymomatous myasthenia gravis: a critical analysis","volume":"1132","author":"Sonett","year":"2008","journal-title":"Ann NY Acad Sci"},{"key":"2021122010012694500_cei12217-bib-0036","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.amjsurg.2010.01.001","article-title":"Comparison of open and minimally invasive thymectomies at a single institution","volume":"199","author":"Youssef","year":"2010","journal-title":"Am J Surg"},{"key":"2021122010012694500_cei12217-bib-0037","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejcts.2009.05.027","article-title":"Thymectomy for non-thymomatous myasthenia gravis: a comparison of surgical methods and analysis of prognostic factors","volume":"37","author":"Lin","year":"2010","journal-title":"Eur J Cardiothorac Surg"},{"key":"2021122010012694500_cei12217-bib-0038","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1196\/annals.1405.014","article-title":"Status of the thymectomy trial for nonthymomatous myasthenia gravis patients receiving prednisone","volume":"1132","author":"Newsom-Davis","year":"2008","journal-title":"Ann NY Acad Sci"},{"key":"2021122010012694500_cei12217-bib-0039","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2165\/11593300-000000000-00000","article-title":"Treatment of myasthenia gravis: focus on pyridostigmine","volume":"31","author":"Maggi","year":"2011","journal-title":"Clin Drug Invest"},{"key":"2021122010012694500_cei12217-bib-0040","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.clineuro.2010.06.018","article-title":"Benefits from sustained-release pyridostigmine bromide in myasthenia gravis: results of a prospective multicenter open-label trial","volume":"112","author":"Sieb","year":"2010","journal-title":"Clin Neurol Neurosurg"},{"key":"2021122010012694500_cei12217-bib-0041","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1196\/annals.1405.022","article-title":"Antisense treatment for myasthenia gravis: experience with monarsen","volume":"1132","author":"Sussman","year":"2008","journal-title":"Ann NY Acad Sci"},{"key":"2021122010012694500_cei12217-bib-0042","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1749-6632.2012.06825.x","article-title":"Further developments with antisense treatment for myasthenia gravis","volume":"1275","author":"Sussman","year":"2012","journal-title":"Ann NY Acad Sci"},{"key":"2021122010012694500_cei12217-bib-0043","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1055\/s-0028-1100928","article-title":"Long-term treatment of refractory myasthenia gravis with immunoadsorption","volume":"133","author":"Wagner","year":"2008","journal-title":"Dtsch Med Wochenschr"},{"key":"2021122010012694500_cei12217-bib-0044","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jns.2007.04.045","article-title":"Myasthenic crisis: guidelines for prevention and treatment","volume":"261","author":"Jani-Acsadi","year":"2007","journal-title":"J Neurol Sci"},{"key":"2021122010012694500_cei12217-bib-0045","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/mus.23508","article-title":"A Retrospective study of complications of therapeutic plasma exchange in myasthenia","volume":"47","author":"Guptill","year":"2013","journal-title":"Muscle Nerve"},{"key":"2021122010012694500_cei12217-bib-0046","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/jca.20317","article-title":"A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis","volume":"26","author":"K\u00f6hler","year":"2011","journal-title":"J Clin Apher"},{"key":"2021122010012694500_cei12217-bib-0047","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"key":"2021122010012694500_cei12217-bib-0048","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ana.22139","article-title":"Comparative analysis of therapeutic options used for myasthenia gravis","volume":"68","author":"Mandawat","year":"2010","journal-title":"Ann Neurol"},{"key":"2021122010012694500_cei12217-bib-0049","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"key":"2021122010012694500_cei12217-bib-0050","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ana.10400","article-title":"Treatment of refractory myasthenia: \u2018rebooting\u2019 with high-dose cyclophosphamide","volume":"53","author":"Drachman","year":"2003","journal-title":"Ann Neurol"},{"key":"2021122010012694500_cei12217-bib-0051","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1471-2377-11-97","article-title":"A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis","volume":"11","author":"Heckmann","year":"2011","journal-title":"BMC Neurol"},{"key":"2021122010012694500_cei12217-bib-0052","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"key":"2021122010012694500_cei12217-bib-0053","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1212\/01.wnl.0000312373.67493.7f","article-title":"A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis","volume":"71","author":"Muscle Study Group","year":"2008","journal-title":"Neurology"},{"key":"2021122010012694500_cei12217-bib-0054","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/mus.21640","article-title":"Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients","volume":"41","author":"Hehir","year":"2010","journal-title":"Muscle Nerve"},{"issue":"Suppl. 1","key":"2021122010012694500_cei12217-bib-0055","first-page":"135","article-title":"Cyclosporin A versus azathioprine in the treatment of myasthenia gravis: final results of a randomized, controlled double-blind clinical trial","volume":"38","author":"Schalke","year":"1988","journal-title":"Neurology"},{"key":"2021122010012694500_cei12217-bib-0056","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1749-6632.1993.tb22937.x","article-title":"A clinical therapeutic trial of cyclosporine in myasthenia gravis","volume":"681","author":"Tindall","year":"1993","journal-title":"Ann NY Acad Sci"},{"key":"2021122010012694500_cei12217-bib-0057","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s004150050141","article-title":"Long-term cyclosporine treatment in a group of severe myasthenia gravis patients","volume":"244","author":"Bonifati","year":"1997","journal-title":"J Neurol"},{"key":"2021122010012694500_cei12217-bib-0058","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000319172","article-title":"Two-year treatment with cyclosporine microemulsion for responder myasthenia gravis patients","volume":"64","author":"Nagane","year":"2010","journal-title":"Eur Neurol"},{"key":"2021122010012694500_cei12217-bib-0059","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1006\/jaut.1996.0111","article-title":"FK506 prevents induction of rat experimental autoimmune myasthenia gravis","volume":"10","author":"Yoshikawa","year":"1997","journal-title":"J Autoimmun"},{"key":"2021122010012694500_cei12217-bib-0060","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1185\/030079907X188080","article-title":"Post-thymectomy combined treatment of prednisone and tacrolimus versus prednisone alone for consolidation of complete stable remission in patients with myasthenia gravis: a non-randomized, non-controlled study","volume":"23","author":"Ponseti","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"2021122010012694500_cei12217-bib-0061","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/mus.10018","article-title":"Successful treatment of myasthenia gravis with tacrolimus","volume":"25","author":"Evoli","year":"2002","journal-title":"Muscle Nerve"},{"key":"2021122010012694500_cei12217-bib-0062","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0025-7753(02)72301-4","article-title":"Tacrolimus (FK506) in the treatment of prednisone-resistant myasthenia gravis. Preliminary results of 20 cases","volume":"118","author":"Ponseti","year":"2002","journal-title":"Med Clin (Barc)"},{"key":"2021122010012694500_cei12217-bib-0063","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jns.2010.09.033","article-title":"Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis","volume":"300","author":"Minami","year":"2011","journal-title":"J Neurol Sci"},{"key":"2021122010012694500_cei12217-bib-0064","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/jnnp-2011-300148","article-title":"Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis","volume":"82","author":"Yoshikawa","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021122010012694500_cei12217-bib-0065","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/j.clinph.2012.01.017","article-title":"Early effect of tacrolimus in improving excitation\u2013contraction coupling in myasthenia gravis","volume":"123","author":"Imai","year":"2012","journal-title":"Clin Neurophysiol"},{"key":"2021122010012694500_cei12217-bib-0066","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/00003495-199958010-00009","article-title":"Rituximab","volume":"58","author":"Onrust","year":"1999","journal-title":"Drugs"},{"key":"2021122010012694500_cei12217-bib-0067","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1517\/14712598.2.1.97","article-title":"Rituximab: clinical development and future directions","volume":"2","author":"Cheson","year":"2002","journal-title":"Expert Opin Biol Ther"},{"key":"2021122010012694500_cei12217-bib-0068","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/cei.12206","article-title":"Requirement for safety monitoring for approved multiple sclerosis therapies: an overview","volume":"175","author":"Rommer","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"2021122010012694500_cei12217-bib-0069","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/cei.12197","article-title":"Monoclonal antibodies in treatment of multiple sclerosis","volume":"175","author":"Rommer","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"2021122010012694500_cei12217-bib-0070","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/mus.23412","article-title":"Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study","volume":"46","author":"Collongues","year":"2012","journal-title":"Muscle Nerve"},{"key":"2021122010012694500_cei12217-bib-0071","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jns.2009.02.357","article-title":"Rituximab for myasthenia gravis: three case reports and review of the literature","volume":"280","author":"Stieglbauer","year":"2009","journal-title":"J Neurol Sci"},{"key":"2021122010012694500_cei12217-bib-0072","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/CND.0b013e3181df2b3e","article-title":"Rituximab in the treatment of MuSK antibody-positive myasthenia gravis","volume":"12","author":"Stein","year":"2011","journal-title":"J Clin Neuromuscul Dis"},{"key":"2021122010012694500_cei12217-bib-0073","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/CND.0b013e31819a8403","article-title":"Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review","volume":"10","author":"Nelson","year":"2009","journal-title":"J Clin Neuromuscul Dis"},{"key":"2021122010012694500_cei12217-bib-0074","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/jnnp.2009.197632","article-title":"The use of rituximab in myasthenia gravis and Lambert\u2013Eaton myasthenic syndrome","volume":"82","author":"Maddison","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021122010012694500_cei12217-bib-0075","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/mus.21521","article-title":"Rituximab in the management of refractory myasthenia gravis","volume":"41","author":"Zebardast","year":"2010","journal-title":"Muscle Nerve"},{"key":"2021122010012694500_cei12217-bib-0076","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1600-0404.2010.01345.x","article-title":"Rituximab for severe myasthenia gravis\u2009\u2013\u2009experience from five patients","volume":"122","author":"Lindberg","year":"2010","journal-title":"Acta Neurol Scand"},{"key":"2021122010012694500_cei12217-bib-0077","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1196\/annals.1405.012","article-title":"Response to therapy in myasthenia gravis with anti-MuSK antibodies","volume":"1132","author":"Evoli","year":"2008","journal-title":"Ann NY Acad Sci"},{"key":"2021122010012694500_cei12217-bib-0078","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/mus.21047","article-title":"Improvement with rituximab in a patient with both rheumatoid arthritis and myasthenia gravis","volume":"38","author":"Kerkeni","year":"2008","journal-title":"Muscle Nerve"},{"issue":"Suppl. 2","key":"2021122010012694500_cei12217-bib-0079","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.3949\/ccjm.78.s2.07","article-title":"PML and rheumatology: the contribution of disease and drugs","volume":"78","author":"Molloy","year":"2011","journal-title":"Cleve Clin J Med"},{"key":"2021122010012694500_cei12217-bib-0080","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/acr.21564","article-title":"Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases","volume":"64","author":"Bharat","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2021122010012694500_cei12217-bib-0081","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jbspin.2011.11.002","article-title":"Progressive multifocal leukoencephalopathy in autoimmune diseases","volume":"79","author":"Palazzo","year":"2012","journal-title":"Joint Bone Spine"},{"key":"2021122010012694500_cei12217-bib-0082","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1002\/art.34468","article-title":"Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies","volume":"64","author":"Molloy","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2021122010012694500_cei12217-bib-0083","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1749-6632.2012.06824.x","article-title":"Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?","volume":"1274","author":"Gomez","year":"2012","journal-title":"Ann NY Acad Sci"},{"key":"2021122010012694500_cei12217-bib-0084","first-page":"939520","article-title":"B-cell-activating factor and autoimmune myasthenia gravis","volume":"2011","author":"Ragheb","year":"2011","journal-title":"Autoimmune Dis"},{"key":"2021122010012694500_cei12217-bib-0085","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1749-6632.2012.06842.x","article-title":"The role of B cell-activating factor in autoimmune myasthenia gravis","volume":"1274","author":"Lisak","year":"2012","journal-title":"Ann NY Acad Sci"},{"key":"2021122010012694500_cei12217-bib-0086","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/archneur.65.10.1358","article-title":"A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis","volume":"65","author":"Ragheb","year":"2008","journal-title":"Arch Neurol"},{"key":"2021122010012694500_cei12217-bib-0087","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mus.23839","article-title":"A randomized, double-blind, placebo-controlled Phase II study of eculizumab in patients with refractory generalized myasthenia gravis","volume":"48","author":"Howard","year":"2013","journal-title":"Muscle Nerve"},{"key":"2021122010012694500_cei12217-bib-0088","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0165-5728(01)00473-8","article-title":"Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein","volume":"122","author":"Christadoss","year":"2002","journal-title":"J Neuroimmunol"},{"key":"2021122010012694500_cei12217-bib-0089","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1212\/01.WNL.0000147242.92691.71","article-title":"Etanercept treatment in corticosteroid-dependent myasthenia gravis","volume":"63","author":"Rowin","year":"2004","journal-title":"Neurology"},{"key":"2021122010012694500_cei12217-bib-0090","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/mus.21280","article-title":"Myasthenia gravis associated with etanercept therapy","volume":"39","author":"Fee","year":"2009","journal-title":"Muscle Nerve"},{"key":"2021122010012694500_cei12217-bib-0091","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1749-6632.2012.06840.x","article-title":"Functional defect in regulatory T cells in myasthenia gravis","volume":"1274","author":"Thiruppathi","year":"2012","journal-title":"Ann NY Acad Sci"},{"key":"2021122010012694500_cei12217-bib-0092","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/mus.23488","article-title":"Granulocyte macrophage colony-stimulating factor treatment of a patient in myasthenic crisis: effects on regulatory T cells","volume":"46","author":"Rowin","year":"2012","journal-title":"Muscle Nerve"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcei.12217","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/175\/3\/408\/41788950\/cei12217.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/175\/3\/408\/41788950\/cei12217.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T16:25:25Z","timestamp":1641054325000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/175\/3\/408\/6421208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,4]]},"references-count":92,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,2,4]]},"published-print":{"date-parts":[[2014,2,4]]}},"URL":"https:\/\/doi.org\/10.1111\/cei.12217","relation":{},"ISSN":["1365-2249","0009-9104"],"issn-type":[{"value":"1365-2249","type":"electronic"},{"value":"0009-9104","type":"print"}],"subject":[],"published-other":{"date-parts":[[2014,3]]},"published":{"date-parts":[[2014,2,4]]}}}